Alector FY2025 EPS Forecast Increased by Cantor Fitzgerald

Alector, Inc. (NASDAQ:ALEC) – Stock analysts at Cantor Fitzgerald raised their FY2025 earnings estimates for Alector in a report released on Thursday, February 27th. Cantor Fitzgerald analyst P. Stavropoulos now forecasts that the company will earn ($2.02) per share for the year, up from their prior estimate of ($2.55). Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Alector’s current full-year earnings is ($1.88) per share.

Alector (NASDAQ:ALEC) last released its earnings results on Wednesday, February 26th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.59. Alector had a negative net margin of 257.54% and a negative return on equity of 108.77%. The business had revenue of $54.24 million during the quarter, compared to analyst estimates of $20.41 million.

A number of other equities research analysts have also issued reports on ALEC. Mizuho lowered shares of Alector from an “outperform” rating to a “neutral” rating and dropped their target price for the stock from $9.00 to $2.50 in a report on Tuesday, December 17th. Stifel Nicolaus lowered shares of Alector from a “buy” rating to a “hold” rating and set a $4.00 target price for the company. in a report on Monday, December 16th. Bank of America lowered shares of Alector from a “neutral” rating to an “underperform” rating and dropped their target price for the stock from $9.00 to $1.00 in a report on Wednesday, December 4th. Morgan Stanley lowered shares of Alector from an “equal weight” rating to an “underweight” rating and dropped their price objective for the company from $10.00 to $3.00 in a report on Tuesday, November 26th. Finally, BTIG Research dropped their price objective on shares of Alector from $16.00 to $5.00 and set a “buy” rating for the company in a report on Tuesday, November 26th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $3.75.

Alector Stock Down 14.0 %

Alector stock opened at $1.41 on Monday. Alector has a 52-week low of $1.38 and a 52-week high of $7.45. The firm has a market capitalization of $139.71 million, a price-to-earnings ratio of -0.83 and a beta of 0.61. The company has a fifty day simple moving average of $1.77 and a 200-day simple moving average of $3.49.

Institutional Investors Weigh In On Alector

Hedge funds have recently modified their holdings of the company. Creative Planning boosted its stake in Alector by 54.2% during the third quarter. Creative Planning now owns 19,117 shares of the company’s stock worth $89,000 after buying an additional 6,723 shares during the period. Victory Capital Management Inc. boosted its stake in Alector by 19.5% during the third quarter. Victory Capital Management Inc. now owns 186,747 shares of the company’s stock worth $870,000 after buying an additional 30,513 shares during the period. Intech Investment Management LLC purchased a new position in Alector during the third quarter worth about $90,000. Massachusetts Financial Services Co. MA boosted its stake in Alector by 54.7% during the third quarter. Massachusetts Financial Services Co. MA now owns 174,718 shares of the company’s stock worth $814,000 after buying an additional 61,798 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its stake in Alector by 14.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 760,606 shares of the company’s stock worth $3,544,000 after buying an additional 94,145 shares during the period. Hedge funds and other institutional investors own 85.83% of the company’s stock.

Alector Company Profile

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.